While several other CBM approaches have investigated metabolism in physiological adipogenesis, obesity, and diabetes (Si et al., 2007; Coskun et al., 2010; Bordbar et al., 2011; Väremo et al., 2013; Montastier et al., 2015) we believe this model would provide the best benchmark for researchers to use for investigating the response to vascular-targeted therapies due to its thorough reconstruction of adipocyte metabolism and inclusion of VEGFR-related pathways. This evidence concerns the gene KDR and obesity disorder.